https://butterflymarketinsider.com/fr/palantir-resultats-multiple-valorisation-2026/ BMInsider fr 2026-08-04T11:59:42+00:00 Palantir croît de 93 % et reste en baisse : en 2026, c’est le multiple qui décide, pas l’activité https://butterflymarketinsider.com/it/palantir-risultati-multiplo-valutazione-2026/ BMInsider it 2026-08-04T11:59:42+00:00 Palantir cresce del 93 % ed è ancora in perdita: nel 2026 decide il multiplo, non il business https://butterflymarketinsider.com/es/palantir-resultados-multiplo-valoracion-2026/ BMInsider es 2026-08-04T11:59:41+00:00 Palantir crece un 93 % y sigue en negativo: en 2026 decide el múltiplo, no el negocio https://butterflymarketinsider.com/en/palantir-earnings-valuation-multiple-compression-2026/ BMInsider en 2026-08-04T11:59:40+00:00 Palantir Grew 93 Percent and Is Still Down for the Year — In 2026 the Multiple Decides, Not the Business https://butterflymarketinsider.com/de/palantir-quartalszahlen-bewertungsvielfaches-multiple-2026/ BMInsider de 2026-08-04T11:59:40+00:00 Palantir wächst 93 Prozent — und steht trotzdem im Minus. 2026 entscheidet das Vielfache, nicht das Geschäft https://butterflymarketinsider.com/fr/astrazeneca-bristol-myers-squibb-fusion-brevets-2026/ BMInsider fr 2026-08-03T12:00:21+00:00 L’acheteur perd 7 % : AstraZeneca importerait trente milliards de dollars de brevets qui expirent https://butterflymarketinsider.com/it/astrazeneca-bristol-myers-squibb-fusione-brevetti-2026/ BMInsider it 2026-08-03T12:00:20+00:00 Chi compra perde il 7 %: AstraZeneca importerebbe trenta miliardi di dollari di brevetti in scadenza https://butterflymarketinsider.com/es/astrazeneca-bristol-myers-squibb-fusion-patentes-2026/ BMInsider es 2026-08-03T12:00:20+00:00 El comprador cae un 7 %: AstraZeneca importaría 30.000 millones de dólares en patentes que vencen https://butterflymarketinsider.com/en/astrazeneca-bristol-myers-squibb-merger-patent-cliff-2026/ BMInsider en 2026-08-03T12:00:19+00:00 The Buyer Falls Seven Percent — AstraZeneca Would Import Thirty Billion Dollars of Patent Expiry https://butterflymarketinsider.com/de/astrazeneca-bristol-myers-squibb-fusion-patentklippe-2026/ BMInsider de 2026-08-03T12:00:18+00:00 Der Käufer verliert sieben Prozent — AstraZeneca würde mit Bristol Myers Squibb 30 Milliarden Dollar Patentablauf einkaufen